PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH

Ítems similars

• Multiple myeloma: challenges with deciding the optimal sequencing strategy
  per: Anushka Walia, et al.
  Publicat: (2023-07-01)
• PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH
  per: Matthew J. Pianko, et al.
  Publicat: (2023-08-01)
• Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
  per: Chieh-Lin Jerry Teng, et al.
  Publicat: (2024-12-01)
• Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
  per: Bin Hu, et al.
  Publicat: (2025-10-01)
• XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX)
  per: Xiao‐Dong Zhu, et al.
  Publicat: (2022-04-01)